AC Immune (NASDAQ:ACIU) Given Average Recommendation of “Hold” by Brokerages

Shares of AC Immune (NASDAQ:ACIU) have been assigned an average rating of “Hold” from the five analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $9.00.

A number of equities research analysts have recently weighed in on ACIU shares. Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st. Jefferies Financial Group reiterated a “buy” rating and set a $7.00 target price on shares of AC Immune in a report on Friday. Finally, Wall Street Zen upgraded AC Immune from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th.

Institutional Investors Weigh In On AC Immune

A number of hedge funds have recently added to or reduced their stakes in ACIU. EFG International AG bought a new stake in shares of AC Immune during the 4th quarter valued at $41,000. Private Advisor Group LLC bought a new stake in AC Immune during the third quarter valued at about $48,000. Sei Investments Co. purchased a new position in shares of AC Immune in the second quarter valued at about $51,000. Goldman Sachs Group Inc. lifted its position in shares of AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock valued at $58,000 after acquiring an additional 5,920 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new position in shares of AC Immune in the third quarter worth about $63,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune Stock Up 1.3%

Shares of ACIU stock traded up $0.04 during trading on Friday, hitting $3.04. The company had a trading volume of 200,044 shares, compared to its average volume of 359,154. The stock’s 50-day moving average is $3.16 and its two-hundred day moving average is $3.01. The stock has a market capitalization of $305.25 million, a price-to-earnings ratio of -3.62 and a beta of 1.64. AC Immune has a 52 week low of $1.43 and a 52 week high of $4.00.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Friday, March 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. AC Immune had a negative return on equity of 84.32% and a negative net margin of 1,642.89%.The company had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.14 million. On average, research analysts predict that AC Immune will post -0.62 EPS for the current fiscal year.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.